Philip Penepent, MD
Internal Medicine · Bowmansville, NYNPI 1265499008
Payments from drug & device makers
Across 1,146 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- AstraZeneca$3K
- Boehringer Ingelheim$3K
- Amgen$2K
- AbbVie$2K
- Lilly USA, LLC$2K
- plus $14K from 51 others
What the payments were for
- Food & beverage$30,595100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,600 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 285 | $260,084 |
| JardianceEmpagliflozin | 108 | $114,840 |
| OzempicSemaglutide | 74 | $88,778 |
| XareltoRivaroxaban | 73 | $80,423 |
| TrulicityDulaglutide | 39 | $69,619 |
| FarxigaDapagliflozin Propanediol | 39 | $50,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $45,411 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $43,952 |
| Repatha SureclickEvolocumab | 49 | $37,325 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,732 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $18,482 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $16,292 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $16,255 |
| EntrestoSacubitril/Valsartan | 18 | $15,812 |
| Icosapent Ethyl | 29 | $13,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $953 | $260,084285 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $3,018 | $139,020131 claims |
| Novo NordiskOzempic | $3,612 | $88,77874 claims |
| Johnson & JohnsonXarelto | $1,560 | $80,42373 claims |
| Lilly USA, LLCTrulicity | $1,743 | $69,61939 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $3,173 | $69,29170 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $998 | $67,14383 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,637 | $43,95229 claims |
| NovartisEntresto | $216 | $15,81218 claims |
| AbbVieSynthroid | $2,293 | $5,12270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bowmansville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.